Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. - Test2 - elhamkhani - TriplyDB

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

http://www.wikidata.org/entity/Q30416847

about

Bisphosphonates and other bone agents for breast cancer Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence Bisphosphonate and risk of cancer recurrence: protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis Minimal residual disease and circulating tumor cells in breast cancer Omentum and bone marrow: how adipocyte-rich organs create tumour microenvironments conducive for metastatic progression Bone-targeted therapy in metastatic breast cancer - all well-established knowledge?Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors.Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice.Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark.Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer.The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.A Novel Prothrombotic Pathway in Systemic Sclerosis Patients: Possible Role of Bisphosphonate-Activated γδ T Cells.Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.Integrins and bone metastasis: integrating tumor cell and stromal cell interactions.Comparison of molecular and immunocytochemical methods for detection of disseminated tumor cells in bone marrow from early breast cancer patients Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study Bone marrow as a reservoir for disseminated tumor cells: a special source for liquid biopsy in cancer patients Preclinical evaluation of sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.Prevention of bone metastases and management of bone health in early breast cancer.Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.Breast cancer at bone metastatic sites: recent discoveries and treatment targets.Adjuvant bisphosphonates in breast cancer treatment Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer.A Canadian national expert consensus on neoadjuvant therapy for breast cancer: linking practice to evidence and beyond Zoledronic acid in breast cancer: latest findings and interpretations Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.

P2860

Q24203656-4CB66DBB-E7B9-44AF-A2BC-BF36DB741947 Q26746212-23CF1318-D9C7-480F-A015-C75FD5BECC49 Q26795493-19307ADD-7B60-4124-A3A5-8A580CD359F6 Q26861586-B44597B8-2D69-4528-B506-2459413DE2E8 Q26861745-5E9E8B3F-2E1A-4226-9F09-04A4F1EE45DA Q27010152-9A37E7CE-3B10-47F9-8E00-F5C785F1A45A Q28076686-4FA2B601-ED2B-4BD7-9223-035FE1653F71 Q28087676-91AC0765-500A-4E70-B422-0B8E17EDB197 Q28551320-D7AAD639-66DA-4E14-8A4D-4B43415166D5 Q30439048-0C645A2A-2452-469C-8173-061CB119C0C7 Q33587199-3C423EB8-F448-4ABB-AC2B-2664D702BBF1 Q33739204-71904565-3409-41D8-93E8-176C3659008F Q33786905-56501298-1857-4835-86ED-601AD13C9C3B Q33801735-9C7FC379-1F7C-4AAD-AA4B-7F63074A21F2 Q34024176-DCD79C3C-CF03-4CEE-AFE6-871036DBF40D Q34075052-F0735B11-AD85-4FDC-B1C4-74B2AB209A2B Q34145863-A8516B17-BBBA-40B9-88CE-0FE7664698AA Q34148693-8A59C7A3-DA00-4973-AB2A-9C71C2CAE310 Q34232366-D1817323-154F-41B7-A971-D20B6852195F Q34348233-90C9A4E4-0196-477E-92A7-C410EC754775 Q34441622-13CAF2BB-5D4A-4FAD-A60B-0FB3D0E6C9FA Q34468675-A9A0A403-E091-4386-864C-428A2747003B Q34520174-DB0FD73E-5D21-4BE7-BFC5-F7698B3C363B Q34547042-0D8BB8A6-41AB-41B6-9D01-D27C01DE774D Q34561406-2A47253C-E104-4591-89FA-061C4842494B Q34583705-F35BE7E8-3CDE-4D76-BC88-0E2A12294903 Q34613485-9AA89BD2-ACE5-4519-9797-919EC1D0F483 Q34613492-23BB08D4-B38E-422F-98CB-57D68D8C6F1F Q34896573-3FBA597A-C703-4179-B95F-728D11D4C356 Q34939979-214A6F05-5976-46AC-96D5-1ABDFD9DF0F3 Q35066934-08025361-EDAA-4EE4-8719-FF17D3907D9F Q35095543-0E6EA233-8A30-459F-B1AC-30CD4F28DD45 Q35172721-D7EA798F-FAF0-48FF-846E-C96FE6E9F1EC Q35239617-AF6E10E9-3C67-4A3E-B755-E6AB7565654E Q35534524-15BD3DDD-06FC-45BF-BA2E-6DD89BC6D1F4 Q35667196-800D76B2-AD6B-488A-976C-1CCB91C38E11 Q35667318-8EC9206D-D625-43F6-8B19-5F5AA5A90FCC Q35750453-A2BC084C-AF49-47CF-BFDC-EC1350C6F47F Q35750472-06812753-0305-48FE-9876-BFD40612288D Q35832193-6998F43B-5790-45E3-93CA-0903022F64FD

P2860

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

http://www.wikidata.org/entity/Q30416847

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effect of zoledronic acid on d ...... el, randomised, phase 2 trial.

@ast

Effect of zoledronic acid on d ...... el, randomised, phase 2 trial.

@en

type

label

Effect of zoledronic acid on d ...... el, randomised, phase 2 trial.

@ast

Effect of zoledronic acid on d ...... el, randomised, phase 2 trial.

@en

prefLabel

Effect of zoledronic acid on d ...... el, randomised, phase 2 trial.

@ast

Effect of zoledronic acid on d ...... el, randomised, phase 2 trial.

@en

P1433

Q30416847-F9C1509D-F8EC-42AB-8A91-843A582AFBA9

P1476

Q30416847-0E2FD9A6-CB79-4BCE-92DA-CA68C0C09E95

P2093

Q30416847-0E3D4CCD-58DF-420B-8563-75C1465C6DD4

Q30416847-0EDEB233-DBFC-4068-A907-DDF1327BAA3C

Q30416847-1BFA720D-28E6-4E3A-97BF-490535D53536

Q30416847-20D4BB9F-7B2A-4553-89C8-B7D037047295

Q30416847-2139F39E-45C8-4B4C-BDD7-B845ECFA497F

Q30416847-2CADBC3A-7FE1-4A18-9F4D-97607C9ED05E

Q30416847-2FFA0A68-17ED-42D6-82DB-518F2F58D5C9

Q30416847-37D008C6-957E-46FE-B486-9415BC3C696B

Q30416847-38C22C6A-30D9-4A8C-9FBB-E19DA38325E4

Q30416847-39336E9F-B724-4DD4-B710-1BB21CA9CFFC

P2860

Q30416847-08D08497-FA34-4E03-A3BA-758A9F24E6C7

Q30416847-0D9209D3-0238-44B3-9B11-015B7F95DBA9

Q30416847-16A27A37-5BE7-4772-94A1-FB6BB4DBDF57

Q30416847-20EA2E66-95BE-48CB-B1B2-5CA411FD3387

Q30416847-246D91AC-447C-49BB-A8CF-49B4FB3C399B

Q30416847-310D9BF5-9548-4150-A0B8-6C902665D3FF

Q30416847-3579AF09-336F-4C2F-8F95-9657957B0987

Q30416847-412C2E9F-3772-4223-A0BF-519325C02331

Q30416847-4348155F-9EEF-4733-A959-8703B0B55BB1

Q30416847-56A59852-5B2C-4053-A283-9502F1A819E0

P304

Q30416847-A6C17C11-61C7-45D2-AE0C-2AD110C8D56F

P31

Q30416847-E9AA838F-C363-4561-915B-8F95BE9F9FE9

P356

Q30416847-30B1BF90-C8F8-47B4-8D7A-56780CDF2AEB

P433

Q30416847-2CEE427D-71C8-402A-A510-B865486B96BC

P478

Q30416847-4FFEFD87-5E25-41F7-8EED-D48882D0A4F4

P50

Q30416847-357356B5-4559-47E7-9BD3-ADDB46A07960

P577

Q30416847-E207AB82-E72B-4F19-B6FD-5B7C7D7CE4FB

P698

Q30416847-FC95E11F-56A3-4E65-97CD-417019375205

P921

Q30416847-D41A77E7-76A9-4AA3-ADD7-88A89F6DABC2

P932

Q30416847-C172B6FF-5B5C-4505-9900-8DBC754AC4C0

P356

S1470-2045(10)70054-1

P1433

The Lancet Oncology

P1476

Effect of zoledronic acid on d ...... el, randomised, phase 2 trial.

@en

P2093

Amjad Ali

http://www.w3.org/2001/XMLSchema#string

Cynthia Ma

http://www.w3.org/2001/XMLSchema#string

Imran Zoberi

http://www.w3.org/2001/XMLSchema#string

Jill Dietz

http://www.w3.org/2001/XMLSchema#string

Jing Zhai

http://www.w3.org/2001/XMLSchema#string

Joanne Mortimer

http://www.w3.org/2001/XMLSchema#string

Katherine Weilbaecher

http://www.w3.org/2001/XMLSchema#string

Kathryn Diemer

http://www.w3.org/2001/XMLSchema#string

Kathryn Trinkaus

http://www.w3.org/2001/XMLSchema#string

Lourdes Ylagan

http://www.w3.org/2001/XMLSchema#string

P2860

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

Antitumor effects of bisphosphonates: promising preclinical evidence.

Intravenous zoledronic acid in postmenopausal women with low bone mineral density.

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Cancer micrometastases.

Mechanisms of osteolytic bone metastases in breast carcinoma.

The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer.

P304

421-428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(10)70054-1

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Mariana Chavez-MacGregor

P577

2010-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20362507

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3792651

http://www.w3.org/2001/XMLSchema#string